- Home
- COCH vs CVKD Comparison
COCH vs CVKD Comparison
Compare COCH & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- CVKD
- Stock Information
- Founded
- COCH 1995
- CVKD 2022
- Country
- COCH United States
- CVKD United States
- Employees
- COCH N/A
- CVKD N/A
- Industry
- COCH Blank Checks
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- COCH Finance
- CVKD Health Care
- Exchange
- COCH Nasdaq
- CVKD Nasdaq
- Market Cap
- COCH 31.6M
- CVKD 33.7M
- IPO Year
- COCH N/A
- CVKD 2023
- Fundamental
- Price
- COCH $1.72
- CVKD $14.17
- Analyst Decision
- COCH Strong Buy
- CVKD Strong Buy
- Analyst Count
- COCH 2
- CVKD 1
- Target Price
- COCH $9.13
- CVKD $32.00
- AVG Volume (30 Days)
- COCH 16.9K
- CVKD 23.7K
- Earning Date
- COCH 05-01-2025
- CVKD 05-08-2025
- Dividend Yield
- COCH N/A
- CVKD N/A
- EPS Growth
- COCH N/A
- CVKD N/A
- EPS
- COCH N/A
- CVKD N/A
- Revenue
- COCH $212,000.00
- CVKD N/A
- Revenue This Year
- COCH $23.16
- CVKD N/A
- Revenue Next Year
- COCH $13.49
- CVKD N/A
- P/E Ratio
- COCH N/A
- CVKD N/A
- Revenue Growth
- COCH N/A
- CVKD N/A
- 52 Week Low
- COCH $1.21
- CVKD $5.70
- 52 Week High
- COCH $3.99
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- COCH 65.35
- CVKD 39.03
- Support Level
- COCH $1.60
- CVKD $13.10
- Resistance Level
- COCH $1.85
- CVKD $16.50
- Average True Range (ATR)
- COCH 0.13
- CVKD 1.08
- MACD
- COCH 0.03
- CVKD -0.20
- Stochastic Oscillator
- COCH 62.26
- CVKD 26.47
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.